98 results about "Polypeptide chain" patented technology

This invention provides a tetrahedral antibody comprising a first, second, third, and fourth domain, wherein the first and second domains are Fab or Fc domains; wherein each of the first and second domains comprise a first polypeptide chain comprising a first N-terminus of the domain, and a second polypeptide chain comprising a second N-terminus of the domain; wherein the first N-terminus of the first domain and the first N-terminus of the second domain are joined to each other by a non-peptidyl linkage, which can be a covalent linkage or a non-covalent linkage between first and second dimerizing polypeptides attached to the first N-termini of the first and second domains, respectively; and wherein the third and fourth domains are attached at their respective C-termini to the second N-termini of the first and second domains, respectively, or the N-termini of the first and second dimerizing polypeptides.

The invention discloses a preparation method of a polymer vesicle capable of crossing a blood brain barrier, and belongs to the field of high polymer materials and medical engineering. The preparation method of the polymer vesicle capable of crossing the blood brain barrier comprises the following steps: synthesizing an amphiphilic block copolymer by utilizing ring-opening polymerization reaction of polycaprolactone and anhydride in an amino acid ring, then assembling the polymer into the polymer vesicle, and modifying a monoclonal antibody of a transferrin receptor on a polypeptide chain. The polymer vesicle prepared by the invention is simple and convenient in preparation process, short in period, good in stability, good in biocompatibility and good in biodegradability, can be used as an excellent carrier of chemotherapeutic drugs, and can effectively realize drug delivery of targeting brain tumor cells across a blood brain barrier. Compared with a commercial drug delivery carrier, the polymer vesicle has the advantage that the permeability of the drug in a bionic blood brain barrier and the targeted uptake rate of brain tumor cells are remarkably improved.

The invention discloses a method for separating an egg white polypeptide chain by adopting a coupling membrane, and particularly relates to the field of egg white polypeptide chains, the method comprises the following steps: S1, mixing fresh egg white with a buffer solution, adjusting the initial acid-base environment and initial temperature of a system, and measuring key basic parameters after dispersion treatment; s3, introducing the pretreated egg white liquid into a first-stage membrane assembly, monitoring separation process parameters, obtaining interception efficiency, dynamically adjusting operation parameters, and enabling permeate liquid to enter a second-stage membrane assembly; s7, monitoring system environment parameters and polypeptide activity, obtaining an activity retention rate, dynamically adjusting supply parameters, and maintaining the polypeptide activity; s8, classifying and collecting products according to molecular weight intervals, evaluating comprehensive separation efficiency, completing separation and verifying product indexes; by constructing an ultrafiltration membrane-nanofiltration membrane-reverse osmosis membrane three-stage coupling separation system and combining a dynamic parameter adjustment mechanism based on interception efficiency, separation selectivity and refined purity, the purity and separation efficiency of a polypeptide product are remarkably improved.

Provided herein are compositions comprising trispecific and / or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and / or trivalent binding proteins and uses of such binding proteins for the treatment and / or prevention of HIV / AIDS.

This application relates to facilitating the selective binding between modified VH and VL domains by introducing amino acids with complementary charges into the two domains at novel positions within these domains. These modifications are particularly useful in the design and generation of multispecific antibodies, such as bispecific antibodies, where charge-pair mutations in VH and VL domains can facilitate desired pairing between specific heavy- and light-chain polypeptides. These charge-pair mutations can be used alone or in combination with additional strategies to promote correct pairing of polypeptide chains.

This invention provides an antibody composition with improved stability, exhibiting reduced fragmentation of the antibody polypeptide chain during manufacturing and subsequent storage. [Solution] This disclosure relates to improved compositions and methods for treating T cell-mediated diseases and disorders (e.g., autoimmune disorders, graft-versus-host diseases, and graft rejection). Provided are antibody-containing anti-αβTCR binding polypeptides comprising at least one amino acid substitution or modification that enhances the stability of the binding polypeptide by reducing fragmentation of the light chain variable region. Methods provided herein generally involve administering an effective amount of a stabilized, humanized binding polypeptide specific to the alpha-beta T cell receptor (αβTCR) to a subject in need thereof.

The invention provides a three-specificity immune cell adapter-cytokine fusion protein for malignant tumor immunotherapy as well as a preparation method and application of the three-specificity immune cell adapter-cytokine fusion protein. The fusion protein comprises a first binding domain, a second binding domain and a cytokine structural domain which are covalently linked to form a single polypeptide chain or polypeptide compound. The first binding domain is specifically bound with a tumor associated antigen, and the target spot of the first binding domain comprises but is not limited to KK-LC-1, MSLN, HER2, Claudin18.2, Claudin6 and PSMA; the second binding domain is specifically bound with a CD3 protein complex on the surface of the T cell; the cytokine domain is IL2, IL15, IL12, IL21 or a functional variant thereof. The invention also relates to a nucleic acid molecule for coding the fusion protein, an expression vector and application thereof. The fusion protein can be used for immunotherapy of malignant tumors such as colon cancer, gastric cancer, breast cancer, liver cancer, lung cancer and cervical cancer, and has a good application prospect. The invention effectively solves the problems of insufficient T cell activation and limited killing in solid tumor immunotherapy in the prior art.

An affinity carrier may have improved alkali resistance. An immunoglobulin-binding protein containing a mutant polypeptide chain, as well as an affinity carrier containing a solid-phase carrier to which the immunoglobulin-binding protein is bound, may be a mutant polypeptide chain having an amino acid sequence having at least 85% identity to an amino acid sequence indicated by any of SEQ ID NO: 1-6 and 57-62, having a predetermined mutation, and having immunoglobulin-binding activity.

A recombinant hemoglobin, a nucleic acid encoding the recombinant hemoglobin, and a preparation method therefor are provided to address the current problems of complex processes, high production costs, and low yields that exist for improving a hemoglobin having a stable tetrameric structure. The recombinant hemoglobin comprises: two or more units of recombinant hemoglobins, the units of recombinant hemoglobins each comprise four polypeptide chains, and the polypeptide chains are two α chains and two β chains. The amino acid sequences of the four polypeptide chains of each unit of recombinant hemoglobin are linked by means of intra-unit linker peptides to form the unit of recombinant hemoglobin, and two or more of the units are linked by means of inter-unit linker peptides.

The invention discloses a bispecific antibody targeting T cells and Her2 positive cells and a fusion protein connected in series with 4-1BBL. Belongs to the technical field of biology. The fusion protein is of a heterotetramer structure formed by connecting two similar heavy polypeptide chains and two similar light polypeptide chains through disulfide bonds, wherein the similar heavy polypeptide chains comprise a heavy chain variable region of a Her2 targeting antibody, a human IgG1 Fc region and a human 4-1BBL extracellular region; the light polypeptide-like chain comprises a light chain variable region of a Her2 targeting antibody, a human antibody light chain constant region and a single chain variable region fragment of a CD3 targeting antibody. The fusion protein can specifically bind to Her2 positive tumor cells and CD3 molecules on the surfaces of T cells at the same time, and provides a key co-stimulation signal by using 4-1BBL connected in series, so that the killing function of the T cells is efficiently activated and enhanced in the local part of the tumor. The fusion protein provides a novel candidate strategy with stronger curative effect, more lasting effect and better safety for immunotherapy of Her2 positive tumors.

The invention relates to aminoacyl-tRNA synthetases that aminoacylate tRNA with 2-Aminoisobutyric acid (Aib), thus enabling the incorporation of the Aib into a growing polypeptide chain during translation, e.g. in eubacterial host cells such as E. coli. For example, but not limited to, the invention relates to new aminoacyl-tRNA synthetases and the uses hereof, as well as a method for producing polypeptides that contain one or more Aib.

The application belongs to the technical field of biological medicine, and relates to an antibacterial polypeptide, a composition and application thereof. The amino acid sequence of the antibacterial polypeptide is shown in SEQ ID NO. 1: KWKIKWPVKWFKM-NH2. Experiments show that the antibacterial polypeptide has broad-spectrum antibacterial activity on gram-positive bacteria and / or gram-negative bacteria, and simultaneously has low cytotoxicity and low hemolyticity. The antibacterial polypeptide provided in the application is composed of 14 amino acids, the polypeptide chain is short, the molecular weight is small, and the antibacterial polypeptide is easy to be artificially synthesized, is a small-molecule polypeptide with high application value, and can be used for preparing a novel antibacterial agent, and has wide application prospects.

This invention proposes a method for screening bisphenol A-specific peptides using molecular simulation, belonging to the field of food safety technology. The method includes the following steps: 1) Through protein stacking and molecular docking, the molecular structure and interactions of bisphenol A-protein cocrystal compounds in a protein structure database are comprehensively analyzed to obtain the receptor protein and the original parent chain; 2) Based on the original parent chain obtained in step 1), the parent peptide is obtained by truncation of the parent peptide segment by analyzing the main active amino acids in the molecular docking results; 3) By performing virtual amino acid mutations on the parent peptide obtained in step 2), a peptide library specifically binding to bisphenol A is constructed, and molecular dynamics is used for preliminary screening of the peptides; 4) The peptide chains screened in step 3) are used as specific recognition elements, and peptides labeled with fluorescein isothiocyanate are used to form specific recognition probes. The specific recognition probes are mixed with bisphenol A, and the peptide sequences with the strongest specific binding ability to bisphenol A are screened based on the different fluorescence differences. This invention is mainly applied to the screening of specific recognition elements for toxic and harmful small molecules, active ingredients, and functional factors. This method avoids the complex preparation steps of antibodies and the cumbersome screening process of aptamers, achieving high-throughput design of specific recognition elements.

Disclosed is a printing ink including a fixing agent including a peptide polymer (having a polypeptide chain), a liquid medium, and a colorant. Also disclosed is a method of manufacturing a printed matter, the method comprising: a step of forming a film containing a printing ink on a substrate by a printing process; and removing the solvent from the film to form a printed film containing the fixing agent and the coloring agent. The polypeptide chain may also include an artificial protein.

The present invention provides a gel temporary plugging agent and its preparation method and application, which belong to the field of oilfield chemical technology. The gel temporary plugging agent provided by the present invention has a three-dimensional network structure formed by cross-linking animal proteins, and can be degraded into linear polypeptide chains in acid under low temperature conditions, thereby achieving a temporary plugging effect; by introducing a reinforcing agent structural unit for enhancement, the plugging performance of the gel temporary plugging agent is ensured, so that it can achieve the plugging of low-temperature reservoirs. The results of the embodiment show that the hardness of the gel temporary plugging agent prepared by the present invention can reach 42.0N, the elasticity can reach 9.50mm, and the plugging pressure can reach 24.69MPa at a permeability of 1105.2mD; the degradation time can be controlled at 1.3 to 4.1d.

Provided is a bone regeneration material that can provide sufficient therapeutic effects when applied to a bone defect site. The bone regeneration material according to the present invention contains a protein (A). The protein (A) has a polypeptide chain (Y) and / or a polypeptide chain (Y'). The total number of the polypeptide chain (Y) and the polypeptide chain (Y') in the protein (A) is 1-100. The polypeptide chain (Y) includes 2-200 contiguous repeats of an amino acid sequence (X), the amino acid sequence (X) being at least one of: the VPGVG sequence (1), which is the amino acid sequence represented by SEQ ID NO: 1; the GVGVP sequence (4), which is the amino acid sequence represented by SEQ ID NO: 4; and the GAHGPAGPK sequence (3), which is the amino acid sequence represented by SEQ ID NO: 3. The polypeptide chain (Y') is derived from the polypeptide chain (Y) by substituting 5% or less of the amino acid residues with lysine and / or arginine residues, and the total number of the lysine and arginine residues is 1-100.

The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.

The invention discloses a PD-L1 cell targeting fusion protein connected in series with a TGFBR2 extracellular domain, IL-2 and a receptor thereof, and an application thereof. Belongs to the technical field of biology. The fusion protein provided by the invention is a heterotetramer formed by connecting two similar heavy polypeptide chains and two similar light polypeptide chains through a disulfide bond. The fusion protein realizes triple functions through a single molecule: tumor specific localization is realized through PD-L1 targeting VHH (Vascular Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus); an immunosuppressive factor TGF-beta in a tumor microenvironment is neutralized through TGFBR2 ECD; effect immune cells expressing a medium affinity IL-2 receptor are selectively activated and amplified by the combination of IL-2 and IL-2R alpha. The PD-L1 inhibitor provided by the invention overcomes the multiple problems of limited curative effect of a single drug, high IL-2 systemic toxicity, tumor microenvironment immunosuppression and the like in the existing PD-(L) 1 inhibitor, and provides technical support for detection, prevention and treatment of PD-L1 positive tumors.

The present disclosure relates to multispecific binding molecules comprising a polypeptide chain comprising, in N- to C-terminal orientation, an antigen binding domain (e.g., an scFv, a sdAb), a dimerization moiety (e.g., an Fc domain), and a Fab component (e.g., VH or VL). Certain aspects relate to multimeric molecules comprising two polypeptide chains, each comprising, in N- to C-terminal orientation, an antigen binding domain (e.g., an scFv, a sdAb), a dimerization moiety (e.g., an Fc domain), and a Fab component (e.g., VH or VL). The multispecific binding molecules may further comprise one or more additional polypeptide chains associated with the Fab component to form a Fab. The disclosure further provides pharmaceutical compositions comprising the multispecific binding molecules, and methods of use of the multispecific binding molecules in antigen-specific immune activation and in therapeutic applications, as well as nucleic acids encoding the multispecific binding molecules, recombinant cells that express the multispecific binding molecules, and methods of producing the multispecific binding molecules.

The invention discloses an oligopeptide composition, a recombinant polypeptide chain, a recombinant nucleic acid molecule and application. The oligopeptide composition comprises at least one oligopeptide, the amino acid sequence of the oligopeptide is the amino acid sequence of an active domain of HAPLN1 protein, and the oligopeptide composition is used for improving the expression quantity of fibroblasts on the HAPLN1 protein and collagen I.

The application provides a kind of bispecific antibody and its preparation and application, the bispecific antibody includes two chains: from N end to C end in order: VH1 (or VL1), L1, VH2, CH1, the first polypeptide chain of Fc, and from N end to C end in order: VL1 (or VH1), L2, VL2, CL, second polypeptide chain.It is realized tumor selective accumulation by being located in the N end of double antibody structure of the binding domain targeted to tumor associated antigen (TAA), and its shield is located in the inside immune checkpoint antibody fragment to the binding activity of immune checkpoint to reduce systemic activity.

The invention relates to a triple-effect T cell adapter for targeting T cell lymphoma TRBC1. The invention discloses a TRBC1-targeted triple-effect T cell adapter which is composed of an Fc region, a hinge region, a first Fab arm and a second Fab arm, and a third targeting module is covalently connected to the C end of the Fc region to form a Y-shaped triple-head antibody. The first Fab arm and the second Fab arm are respectively combined with TRBC1 and CD3, and the third Fab arm is combined with CD28 or CD137, so that three functions of tumor recognition, T cell recruitment and co-stimulation amplification are integrated. The two polypeptide chains are heterodimerized through CH3 region button mutation, and correct assembly is ensured. The structure supports module interchange, programmable regulation and control of synergistic signals, significantly enhances TRBC1 positive T cell lymphoma killing, reduces toxicity to normal T cells, has high activity and a wide safety window, and is suitable for preparation of related drugs.

The present disclosure relates to the production of multimeric polypeptides (e.g., comprising two or more subunits, each subunit comprising two or more polypeptide chains, such as a multispecific or bispecific antibody) in eukaryotic host cells. In some embodiments, provided herein are methods for producing a multimeric polypeptide in a eukaryotic host cell using a host cell that comprises a polynucleotide comprising a translation initiation sequence operably linked to an open-reading frame encoding each polypeptide of the multimeric polypeptide. Advantageously, the present disclosure demonstrates that tuning the strength of the translation initiation sequences linked to each open-reading frame allows for higher production of the multimeric polypeptide with fewer incorrectly assembled side products. The present disclosure further provides cells, methods of screening, and kits related thereto.

The application discloses a kind of block copolymer polypeptides, polymer fiber and its preparation method and purposes.The block copolymer polypeptide includes dendritic polymer and polypeptide chain connected with the dendritic polymer, the polypeptide chain is composed of structural unit shown in formula I and structural unit shown in formula II, the dendritic polymer is connected with the structural unit shown in formula I by amide bond, the structural unit shown in formula I is connected with the structural unit shown in formula II by amide bond;And.The block copolymer polypeptide of the application can make the functional unit that should form beta-fold conformation with metastable alpha-helix chain growth, later can be converted into beta-fold again metastable alpha-helix, and good stability;The polymer fiber formed has high mechanical property, can be widely used in high toughness composite, degradable biomedical materials and intelligent drug delivery system and other key fields.

A diagnostic, preventive, or therapeutic agent may be used for a myeloproliferative neoplasm. An antibody or a functional fragment thereof that binds to a cleaved mutant CALR protein, may include an antigen-recognition site in (a) a polypeptide chain having an amino acid sequence set forth in SEQ ID NO: 1 or (b) a polypeptide chain having an amino acid sequence having deletion, substitution, or addition of one to several amino acids in SEQ ID NO: 1; and a diagnostic, preventive, or therapeutic agent for a myeloproliferative neoplasm containing the antibody.

The invention relates to the field of enzyme engineering and molecular biology, and discloses a heterologous virus-derived chimeric multifunctional 5 '-'capping' enzyme, and the mRNA vaccine 5 '-'capping' enzyme is formed by sequentially connecting an RNA triphosphatase functional domain derived from rabbit fibroma virus, a guanylyl transferase functional domain and a methyltransferase functional domain derived from flavivirus NS5 protein. According to the invention, RNA triphosphatase, guanylyl transferase and a methyltransferase structural domain with a dual methylation function are integrated into a single polypeptide chain, so that a catalytic process of completing synthesis of a 5'cap 'structure of the mRNA vaccine by one enzyme and one step is realized, the modification process flow of the mRNA vaccine is remarkably simplified, and the consistency and reproducibility of mRNA vaccine production are improved.

The present disclosure provides a use of a dimer in the preparation of a medicament for treating a tumor in a subject in need thereof, and the dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4. The present disclosure also provides a method for treating a tumor in a subject in need thereof, wherein the subject is resistant to the therapy of an immune checkpoint inhibitor.

The present invention relates to DNA constructs comprising a novel TIS sequence. The TIS sequence transcribes into an RNA motif that functions as the protein translation initiation site in an mRNA transcript. The DNA construct may further comprise a nucleic acid sequence encoding signal peptide. Additionally, the DNA constructs may also comprise a nucleic acid sequence encoding a recombinant protein or one or more polypeptide chains thereof. The invention further relates to an expression vector, expression cassette and host cell which comprise said DNA constructs. Furthermore, the present invention relates to a recombinant protein expressed by the host cell as well as a method for expressing the recombinant protein.

The present invention provides a recombinant hemoglobin, a nucleic acid encoding the same, and a method for producing the same, in order to improve the stability of hemoglobin having a tetrameric structure and solve problems such as complicated processes, high production costs, and low yields. The recombinant hemoglobin comprises four polypeptide chains, each of which is composed of two α chains and two β chains. The amino acid sequences of the four polypeptide chains are connected by a linker peptide, and preferably, the linker peptide sequentially connects the amino acid sequences of the four polypeptide chains in any order from the N-terminus to the C-terminus.

The invention relates to a multi-target molecular ligand as well as a preparation method and application thereof. The multi-targeting molecular ligand disclosed by the invention aims at prostate cancer and bone metastasis thereof, and the ligand simultaneously contains a polypeptide chain Glu-urea-Lys (ACUPA) capable of being recognized by a prostate specific membrane antigen (PSMA), is used for targeting diphosphoric acid of hydroxyapatite nanocrystals in bones, and is also combined with an anisidine fragment which is specifically combined with a Sigma-1 receptor. The multi-target molecular ligand can efficiently mark radionuclide and has excellent radiation stability, cell and animal experiments prove that the multi-target molecular ligand can be efficiently taken by PSMA positive prostate cancer RM-1 cells, RM-1 subcutaneous tumor models and RM-1 tibial metastatic tumor models, and can be used for developing diagnosis and treatment of PSMA positive prostate cancer and bone metastasis thereof, and diagnosis and treatment integration is achieved.